YOKNEAM, ISRAEL -- (MARKET WIRE) -- 10/26/2009 --
Syneron Medical Ltd. (NASDAQ: ELOS) today announced that its board of
directors has approved an amendment to the Rights Agreement by and
between Syneron Medical Ltd. and American Stock Transfer & Trust
Company, LLC, dated November 11, 2008. The amendment: (i) extends the
final expiration date of the rights to purchase ordinary shares of the
company issued pursuant to the Rights Agreement to November 30, 2010,
and (ii) effective upon the consummation of the transactions
contemplated by the Agreement and Plan of Merger, dated as of September 8,
2009, among the company, Syneron Acquisition Sub, Inc. and Candela
Corporation, amends the Rights Agreement to provide that each right shall
entitle the holder thereof to purchase from the company one and a quarter
(1.25) ordinary shares at a price of $0.01 per ordinary share, subject to
adjustment in accordance with the terms of the Rights Agreement. No other
terms of the Rights Agreement are modified by the amendment. Prior to the
amendment, the final expiration date of the Rights was November 9, 2009,
and each right entitled the holder thereof to purchase from the company two
(2) ordinary shares at a price of $0.01 per ordinary share.

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: ELOS) manufactures and distributes medical
aesthetic devices that are powered by the proprietary, patented elos
combined-energy technology of Bi-Polar Radio Frequency and Light. The
Company's innovative elos technology provides the foundation for highly
effective, safe and cost-effective systems that enable physicians to
provide advanced solutions for a broad range of medical-aesthetic
applications including hair removal, wrinkle reduction, rejuvenating the
skin's appearance through the treatment of superficial benign vascular and
pigmented lesions, and the treatment of acne, leg veins and cellulite.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for
Syneron Medical Ltd. are located in Israel. Syneron has offices and
distributors throughout the world, including North American headquarters in
Irvine, CA, and Asia-Pacific headquarters in Hong Kong, which provide
sales, service and support. Additional information can be found at
www.syneron.com.

This press release contains forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995 relating to
future events or our future performance. Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity,
performance or achievements expressed or implied in those forward-looking
statements. These risks and other factors are summarized under the heading
"Risk Factors" in our Annual Report on Form 20-F for the year ended
December 31, 2008, filed with the Securities and Exchange Commission on
March 24, 2009. These factors are updated from time to time through the
filing of reports and registration statements with the Securities and
Exchange Commission. We do not assume any obligation to update the
forward-looking information contained in this press release.

Syneron, the Syneron logo, and elos are trademarks of Syneron Medical Ltd.
and may be registered in certain jurisdictions. Elos (Electro-Optical
Synergy) is a proprietary technology of Syneron Medical. All other names
are the property of their respective owners.

Syneron Contacts:
Fabian Tenenbaum
Chief Financial Officer
+ 972 73 244 2283
email: Email Contact

Judith Kleinman
VP Investor Relations
+972 54 646 1688
email: Email Contact